TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01816334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study: NCT02765139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaging Men through Accountable Practice
Description: Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.

Intervention type: OTHER
Group type: OTHER
Intervention: Alternative intervention
Description: Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
Study: NCT03840031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fe OFSP meal labelled with Fe-58
Description: 400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control OFSP meal labelled with Fe-57
Description: 400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
Study: NCT03544567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
Study: NCT03136978

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of M1 and M2 macrophages by flow cytometry.
Description: To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of M1 and M2 macrophages by flow cytometry.
Description: To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
Study: NCT01807780

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological monitoring
Study: NCT03830489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol
Description: The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol plus ascorbic acid
Description: The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
Study: NCT01589458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
Study: NCT02656303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib tablets
Study: NCT02342574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound
Study: NCT03097068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: 0.3mg Lucentis
Study: NCT00617240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
Study: NCT04870840

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04870840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04537715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral 200 mg itraconazole once daily on Days 18 - 38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral 600 mg rifampin once daily on Days 17 - 25.
Study: NCT02342574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT04563312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
Study: NCT02342574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT02418338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speckle tracking (2D strain) echocardiography
Description: 2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: speckle tracking (2D strain) echocardiography
Description: 2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
Study: NCT03562923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study: NCT05645263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting Coca-cola
Description: The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting Coca-cola
Description: The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting Coca-cola
Description: The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
Study: NCT02716519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Santyl
Description: Collagenase ointment applied topically once per day for up to six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
Study: NCT01578603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 6 g/day, for a month, by chewing 2g three times daily after meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: casein phosphopeptide amorphous calcium phosphate complex
Description: two pieces of the commercial presentation three times daily after meals
Study: NCT00433771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex™ Biliary Fully Covered Metal Stent placement
Description: Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
Study: NCT00605839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoPak
Description: We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Phone
Description: We will provide cell phones and access to the clinic to facilitate communications

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: This intervention was usual care, without either device.
Study: NCT03491800

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Question/Topic Prompt List
Description: A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
Study: NCT04625907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent
Study: NCT01294995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea-flavor Liquor
Description: 30 mL of Tea-flavor Liquor(45% alcohol content)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Guizhou Meijiao Liquor
Description: 30 mL of Guizhou Meijiao Liquor (45% alcohol content)
Study: NCT02052739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Solution for injection for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Solution for injection for IV infusion
Study: NCT04625907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinca alkaloid with a role as an antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinca alkaloid with a role as an antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: oral antineoplastic alkylating agent

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
Study: NCT00602927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
Study: NCT01365741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upright position
Description: The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
Study: NCT00499252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study: NCT01974869

Intervention type: DRUG
Intervention: Anti-tumor necrosis factor alpha agents
Description: Treatment with biologics
Study: NCT00535873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
Study: NCT02973178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scanadu Urine Device
Description: Device to allow lay user to perform urinalysis test at home.

Intervention type: DEVICE
Group type: OTHER
Intervention: Scanadu Urine Device
Description: Device to allow lay user to perform urinalysis test at home.

Intervention type: DEVICE
Group type: OTHER
Intervention: Scanadu Urine Device
Description: Device to allow lay user to perform urinalysis test at home.
Study: NCT03476837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
Study: NCT01982045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AttraX® Putty
Description: Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
Study: NCT02416089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampostat

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condom catheter tamponade
Study: NCT03217474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLDEB
Description: The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Description: Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir (GCV)
Description: Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation.
Study: NCT02188927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of ANL
Description: Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No included ANL
Description: Sending Standard Invitation only six weeks before planned screening colonoscopy